Tenaya Therapeutics Reports Positive Gene Therapy Data for Rare Heart Disease Despite Stock Decline Following $60M Offering
Key Insights
Tenaya Therapeutics reported encouraging interim data from its RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for arrhythmogenic right ventricular cardiomyopathy (search), showing improved arrhythmia burden and good tolerability.
The FDA lifted the clinical hold on Tenaya's MyPEAK-1 Phase 1b/2a trial of TN-201 for MYBPC3 (search)-associated hypertrophic cardiomyopathy (search), allowing the company to resume dosing.
The company completed a $60 million equity offering of 50 million units at $1.20 per unit to fund ongoing development of its cardiac gene therapy programs.
Tenaya Therapeutics reported encouraging interim data from its RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for arrhythmogenic right ventricular cardiomyopathy (search) (ARVC (search)) while simultaneously completing a $60 million equity offering that sent shares tumbling despite the positive clinical developments.
The gene therapy company's stock declined 37.44% to 85 cents following the announcement of its underwritten public offering of 50 million units priced at $1.20 per unit. Each unit consists of one share and a warrant to purchase one share of common stock at an exercise price of $1.50 per share.
TN-401 Shows Promise in Rare Heart Disease
The interim data from the RIDGE-1 trial focuses on three patients who received TN-401 at a dose of 3E13 vg/kg, with patient follow-up ranging from 20 to 40 weeks post-dose as of the October 2025 data cut-off. ARVC (search) is a form of arrhythmogenic cardiomyopathy (search) that primarily impacts the right ventricle, caused by mutations in the plakophilin-2 (search) gene, PKP2 (search).
TN-401 demonstrated a favorable safety profile with no incidents of thrombotic microangiopathy (TMA) or cardiotoxicities observed. The therapy increased PKP2 (search) protein expression from baseline in two of three patients and showed evidence of meaningful improvements in arrhythmia burden. To date, no implantable cardioverter-defibrillator (ICD) shocks or arrhythmias associated with TN-401 have occurred, and all patients have successfully tapered off immunosuppressive medicines.
The company has completed enrollment and dosing of three patients at the higher 6E13 vg/kg dose in cohort two, with no new serious adverse events related to TN-401 reported in this cohort. Biopsies demonstrate robust transduction and expression detected in all patients within the first eight weeks, and clinically meaningful improvements in electrical instability were observed in the first two patients with greater than six months of follow-up.
FDA Lifts Clinical Hold on Second Program
Tenaya also received official notification from the FDA that the clinical hold on the MyPEAK-1 Phase 1b/2a trial of TN-201 has been removed. TN-201 is being developed for the potential treatment of Myosin Binding Protein C3 (MYBPC3 (search))-associated hypertrophic cardiomyopathy (search).
Funding Strategy and Market Response
The company plans to use the proceeds from the equity offering to fund ongoing and planned development of its clinical and early-stage product candidates, particularly TN-201 and TN-401, along with working capital and other general corporate purposes. The offering addresses previous concerns about the company's cash runway of less than a year.
Despite the positive clinical developments, the stock experienced significant selling pressure with session volume reaching 42.39 million compared to the average volume of 3.51 million. The Simply Wall St Community's fair value estimates for Tenaya span roughly $0.96 to $9.57 per share, reflecting the wide range of investor perspectives on the company's prospects following the trial updates and dilutive financing.
Tenaya's AAV9 gene therapy platform targets the genetic root causes of serious inherited heart diseases, representing a potential first-in-class approach to treating these rare conditions with one-time treatments. The company remains pre-revenue and dependent on capital markets to advance its pipeline, with near-term catalysts including further TN-401 arrhythmia readouts and resumed TN-201 dosing.